Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Рынки
Скринер
Новости
О нас

Home

IMVT

I

Immunovant, Inc. (IMVT)

NMS – Цена в реальном времени. Валюта: USD

23.98

-1.38 (-5.44%)

При закрытии: Mar 27, 2026, 4:00 PM EDT

23.84

-0.14 (-0.56%)

После закрытия: Mar 27, 2026, 6:31 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

A Healthcare Hedge Fund Just Added $24.5 Million in Immunovant Stock. Should you?

Logos added 1.1 million shares of Immunovant last quarter, a purchase estimated at about $24.5 million based on quarterly average pricing. By quarter's end, the position had grown to roughly $35 million, reflecting both the new shares and price gains during the period.

Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish

Immunovant Stock Up 30% as Investor Trims Stake by $3 Million, But Here's Why It Still Seems Bullish

Alpine Global Management sold 128,039 shares of Immunovant in the fourth quarter; the estimated transaction value was $2.8 million based on quarterly average prices. Meanwhile, the quarter-end position value decreased by $22 million, reflecting both trading and stock price changes.

Immunovant Stock Surges 17% in 3 Months: What's Driving It?

Immunovant Stock Surges 17% in 3 Months: What's Driving It?

IMVT gains 17% in three months as IMVT-1402 advances across autoimmune trials, with multiple data readouts due in 2026-2027, and $994.5M cash backing development.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ:IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.

IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus

IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus

Immunovant beats third-quarter estimates, raises $550M to fund IMVT-1402 through launch and advances multiple studies with key data ahead.

Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript

Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript

Immunovant, Inc. (IMVT) Q3 2026 Earnings Call Transcript

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported its financial results for the third quarter ended December 31, 2025.

Видео

No Data

There is no data to display

Пресс-релизы

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

NEW YORK, Feb. 17, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ:IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

DURHAM, N.C., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported its financial results for the third quarter ended December 31, 2025.

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Immunovant, Inc. (NASDAQ: IMVT)

NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Immunovant, Inc. (NASDAQ: IMVT) on behalf of the company's shareholders. The investigation seeks to determine whether Immunovant, Inc.'s directors breached their fiduciary duties in connection with recent corporate actions.

Immunovant Announces Pricing of $550 Million Common Stock Financing

Immunovant Announces Pricing of $550 Million Common Stock Financing

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced the pricing of an underwritten offering of its common stock, with anticipated gross proceeds to Immunovant of approximately $550 million, before deducting underwriting discounts and commissions and other expenses payable by Immunovant in connection with the transaction. Roivant Sciences Ltd., the Company's controlling stockholder, has agreed to purchase shares in the offering. All of the shares are to be sold by Immunovant.